Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Kullak-Ublick GA, Stieger B, Meier PJ: Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology126,322–342 (2004).
  Medline CASGoogle Scholar
• 2  Glaeser H, Bailey DG, Dresser GK et al.: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther.81,362–370 (2007).
  Medline CASGoogle Scholar
• 3  Meier Y, Eloranta JJ, Darimont J et al.: Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos.35,590–594 (2007).
  Medline CASGoogle Scholar
• 4  Chan LM, Lowes S, Hirst BH: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci.21,25–51 (2004).
  Medline CASGoogle Scholar
• 5  Zuber R, Anzenbacherova E, Anzenbacher P: Cytochromes P450 and experimental models of drug metabolism. J. Cell. Mol. Med.6,189–198 (2002).
  Medline CASGoogle Scholar
• 6  Cascorbi I: Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther.112,457–473 (2006).
  Medline CASGoogle Scholar
• 7  Halestrap AP, Meredith D: The SLC16 gene family – from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch.447,619–628 (2004).
  Medline CASGoogle Scholar
• 8  Evseenko D, Paxton JW, Keelan JA: Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin. Drug Metab. Toxicol.2,51–69 (2006).
  Medline CASGoogle Scholar
• 9  Suzuki T, Onogawa T, Asano N et al.: Identification and characterization of novel rat and human gonad-specific organic anion transporters. Mol. Endocrinol.17,1203–1215 (2003).
  Medline CASGoogle Scholar
• 10  Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos.35,1333–1340 (2007).
  Medline CASGoogle Scholar
• 11  Freeman TC, Bentsen BS, Thwaites DT, Simmons NL: H⁺/di-tripeptide transporter (PepT1) expression in the rabbit intestine. Pflugers Arch.430,394–400 (1995).
  Medline CASGoogle Scholar
• 12  Brandsch M, Brandsch C, Ganapathy ME, Chew CS, Ganapathy V, Leibach FH: Influence of proton and essential histidyl residues on the transport kinetics of the H⁺/peptide cotransport systems in intestine (PEPT 1) and kidney (PEPT 2). Biochim. Biophys. Acta1324,251–262 (1997).
  Medline CASGoogle Scholar
• 13  Dantzig AH, Bergin L: Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim. Biophys. Acta1027,211–217 (1990).
  Medline CASGoogle Scholar
• 14  Satake M, Enjoh M, Nakamura Y et al.: Transepithelial transport of the bioactive tripeptide, Val–Pro–Pro, in human intestinal Caco-2 cell monolayers. Biosci. Biotechnol. Biochem.66,378–384 (2002).
  Medline CASGoogle Scholar
• 15  Anderle P, Nielsen CU, Pinsonneault J, Krog PL, Brodin B, Sadee W: Genetic variants of the human dipeptide transporter PEPT1. J. Pharmacol. Exp. Ther.316,636–646 (2006).•  Highlights the need for further trials investigating the effects of PEPT1 polymorphisms on drug transport.
  Medline CASGoogle Scholar
• 16  Zhang EY, Fu DJ, Pak YA et al.: Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: implications for the functional role of Pro586. J. Pharmacol. Exp. Ther.310,437–445 (2004).
  Medline CASGoogle Scholar
• 17  Sala-Rabanal M, Loo DD, Hirayama BA, Turk E, Wright EM: Molecular interactions between dipeptides, drugs and the human intestinal H⁺-oligopeptide cotransporter hPEPT1. J. Physiol.574,149–166 (2006).• PEPT1 polymorphisms and the transport of dipeptide drugs.
  Medline CASGoogle Scholar
• 18  Yabuuchi H, Tamai I, Nezu J et al.: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther.289,768–773 (1999).
  Medline CASGoogle Scholar
• 19  Wu X, Huang W, Prasad PD et al.: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J. Pharmacol. Exp. Ther.290,1482–1492 (1999).
  Medline CASGoogle Scholar
• 20  Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Krissansen GW: Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn’s disease in a New Zealand Caucasian cohort. Immunol. Cell. Biol.84,233–236 (2006).
  Medline CASGoogle Scholar
• 21  Palmieri O, Latiano A, Valvano R et al.: Variants of OCTN1–2 cation transporter genes are associated with both Crohn’s disease and ulcerative colitis. Aliment. Pharmacol. Ther.23,497–506 (2006).
  Medline CASGoogle Scholar
• 22  Peltekova VD, Wintle RF, Rubin LA et al.: Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet.36,471–475 (2004).
  Medline CASGoogle Scholar
• 23  Urban TJ, Brown C, Castro RA et al.: Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin. Pharmacol. Ther.83(3),416–421 (2008).•• Important clinical phenotype–genotype study.
  Medline CASGoogle Scholar
• 24  Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol.276,F122–F128 (1999).
  Medline CASGoogle Scholar
• 25  Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J. Pharmacol. Exp. Ther.301,293–298 (2002).
  Medline CASGoogle Scholar
• 26  Babu E, Takeda M, Narikawa S et al.: Human organic anion transporters mediate the transport of tetracycline. Jpn J. Pharmacol.88,69–76 (2002).
  Medline CASGoogle Scholar
• 27  Xu G, Bhatnagar V, Wen G, Hamilton BA, Eraly SA, Nigam SK: Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int.68,1491–1499 (2005).
  Medline CASGoogle Scholar
• 28  König J, Seithel A, Gradhand U, Fromm MF: Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol.372,432–443 (2006).
  MedlineGoogle Scholar
• 29  Hagenbuch B, Meier PJ: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta1609,1–18 (2003).
  Medline CASGoogle Scholar
• 30  Hagenbuch B, Meier PJ: Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch.447,653–665 (2004).• Excellent general review of the OATP family.
  Medline CASGoogle Scholar
• 31  Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T: The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet.19,171–179 (2004).
  Medline CASGoogle Scholar
• 32  Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature372,549–552 (1994).
  Medline CASGoogle Scholar
• 33  Koepsell H, Lips K, Volk C: Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res.24,1227–1251 (2007).
  Medline CASGoogle Scholar
• 34  Meyer-Wentrup F, Karbach U, Gorboulev V, Arndt P, Koepsell H: Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem. Biophys. Res. Commun.248,673–678 (1998).
  Medline CASGoogle Scholar
• 35  Gorboulev V, Ulzheimer JC, Akhoundova A et al.: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol.16,871–881 (1997).
  Medline CASGoogle Scholar
• 36  Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol.51,913–921 (1997).
  Medline CASGoogle Scholar
• 37  Sakata T, Anzai N, Shin HJ et al.: Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem. Biophys. Res. Commun.313,789–793 (2004).
  Medline CASGoogle Scholar
• 38  Itoda M, Saito Y, Maekawa K et al.: Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab. Pharmacokinet.19,308–312 (2004).
  MedlineGoogle Scholar
• 39  Takeuchi A, Motohashi H, Okuda M, Inui K: Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metab. Pharmacokinet.18,409–412 (2003).
  Medline CASGoogle Scholar
• 40  Shu Y, Leabman MK, Feng B et al.: Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl Acad. Sci. USA100,5902–5907 (2003).
  Medline CASGoogle Scholar
• 41  Leabman MK, Huang CC, DeYoung J et al.: Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc. Natl Acad. Sci. USA100,5896–5901 (2003).
  Medline CASGoogle Scholar
• 42  Kerb R, Brinkmann U, Chatskaia N et al.: Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics12,591–595 (2002).
  Medline CASGoogle Scholar
• 43  Kang HJ, Song IS, Shin HJ et al.: Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab. Dispos.35,667–675 (2007).
  Medline CASGoogle Scholar
• 44  Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther.302,510–515 (2002).
  Medline CASGoogle Scholar
• 45  Shu Y, Sheardown SA, Brown C et al.: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest.117,1422–1431 (2007).•• Associates a patient’s genotype with their phenotype upon metformin treatment.
  Medline CASGoogle Scholar
• 46  Shikata E, Yamamoto R, Takane H et al.: Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J. Hum. Genet.52,117–122 (2007).
  Medline CASGoogle Scholar
• 47  Kullak-Ublick GA, Ismair MG, Stieger B et al.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology120,525–533 (2001).
  Medline CASGoogle Scholar
• 48  König J, Cui Y, Nies AT, Keppler D: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol.278,G156–G164 (2000).
  Medline CASGoogle Scholar
• 49  Abe T, Kakyo M, Tokui T et al.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem.274,17159–17163 (1999).
  Medline CASGoogle Scholar
• 50  Niemi M, Schaeffeler E, Lang T et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics14,429–440 (2004).
  Medline CASGoogle Scholar
• 51  Nozawa T, Nakajima M, Tamai I et al.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther.302,804–813 (2002).
  Medline CASGoogle Scholar
• 52  Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European– and African–Americans. J. Biol. Chem.276,35669–35675 (2001).•• Important study on the pharmacogenetics of the OATP1B1 haplotypes.
  Medline CASGoogle Scholar
• 53  Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K: Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther.83,251–257 (2008).
  Medline CASGoogle Scholar
• 54  Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y: Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics14,749–757 (2004).
  Medline CASGoogle Scholar
• 55  Hsiang B, Zhu Y, Wang Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem.274,37161–37168 (1999).
  Medline CASGoogle Scholar
• 56  Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics15,513–522 (2005).
  Medline CASGoogle Scholar
• 57  Nishizato Y, Ieiri I, Suzuki H et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther.73,554–565 (2003).• Looks at the effects of OATP1B1 genetic variants on the transport of statins.
  Medline CASGoogle Scholar
• 58  Tachibana-Iimori R, Tabara Y, Kusuhara H et al.: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet.19,375–380 (2004).
  Medline CASGoogle Scholar
• 59  Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther.75,415–421 (2004).
  Medline CASGoogle Scholar
• 60  Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K: A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab. Pharmacokinet.19,453–455 (2004).• Important study highlighting the effects of genetic drug transporter variants on drug-induced myopathy.
  Medline CASGoogle Scholar
• 61  Gerloff T, Schaefer M, Mwinyi J et al.: Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin’s cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmiedebergs Arch. Pharmacol.373,45–50 (2006).
  Medline CASGoogle Scholar
• 62  Ho RH, Tirona RG, Leake BF et al.: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology130,1793–1806 (2006).
  Medline CASGoogle Scholar
• 63  Chung JY, Cho JY, Yu KS et al.: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther.78,342–350 (2005).
  Medline CASGoogle Scholar
• 64  Lee E, Ryan S, Birmingham B et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther.78,330–341 (2005).
  Medline CASGoogle Scholar
• 65  Zhang W, He YJ, Han CT et al.: Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol.62,567–572 (2006).
  Medline CASGoogle Scholar
• 66  Niemi M, Backman JT, Kajosaari LI et al.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther.77,468–478 (2005).
  Medline CASGoogle Scholar
• 67  Ieiri I, Suzuki H, Kimura M et al.: Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatol. Res.30,91–95 (2004).
  Medline CASGoogle Scholar
• 68  Michalski C, Cui Y, Nies AT et al.: A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem.277,43058–43063 (2002).
  Medline CASGoogle Scholar
• 69  Iida A, Saito S, Sekine A et al.: Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. J. Hum. Genet.46,668–683 (2001).• One of the largest genetic screening studies evaluating OATP SNP distribution.
  Medline CASGoogle Scholar
• 70  Furihata T, Satoh T, Yamamoto N, Kobayashi K, Chiba K: Hepatocyte nuclear factor 1 α is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm. Res.24,2327–2332 (2007).•• Impact of transcription factors on drug-transporter function.
  Medline CASGoogle Scholar
• 71  Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA: Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 α. J. Biol. Chem.276,37206–37214 (2001).
  Medline CASGoogle Scholar
• 72  König J, Cui Y, Nies AT, Keppler D: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem.275,23161–23168 (2000).
  Medline CASGoogle Scholar
• 73  Abe T, Unno M, Onogawa T et al.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology120,1689–1699 (2001).
  Medline CASGoogle Scholar
• 74  Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y: Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab. Pharmacokinet.21,165–169 (2006).
  MedlineGoogle Scholar
• 75  Letschert K, Keppler D, Konig J: Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics14,441–452 (2004).
  Medline CASGoogle Scholar
• 76  Smith NF, Marsh S, Scott-Horton TJ et al.: Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther.81,76–82 (2007).
  Medline CASGoogle Scholar
• 77  Ismair MG, Stieger B, Cattori V et al.: Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology121,1185–1190 (2001).
  Medline CASGoogle Scholar
• 78  Jung D, Podvinec M, Meyer UA et al.: Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology122,1954–1966 (2002).
  Medline CASGoogle Scholar
• 79  Marzolini C, Tirona RG, Gervasini G et al.: A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol.21,1769–1780 (2007).•• Detailed study of the effects of nuclear receptor polymorphisms on drug transporters.
  Medline CASGoogle Scholar
• 80  van Mil SW, Milona A, Dixon PH et al.: Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology133,507–516 (2007).•• Detailed study of the effects of nuclear receptor polymorphisms on drug transporters.
  Medline CASGoogle Scholar
• 81  Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther.306,703–708 (2003).
  Medline CASGoogle Scholar
• 82  Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther.308,438–445 (2004).
  MedlineGoogle Scholar
• 83  Tamai I, Nezu J, Uchino H et al.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun.273,251–260 (2000).
  Medline CASGoogle Scholar
• 84  Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y: A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl Acad. Sci. USA102,17923–17928 (2005).
  Medline CASGoogle Scholar
• 85  Masuda S, Terada T, Yonezawa A et al.: Identification and functional characterization of a new human kidney-specific H⁺/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol.17,2127–2135 (2006).
  Medline CASGoogle Scholar
• 86  Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K: Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(⁺)-organic cation antiporters. Biochem. Pharmacol.74,359–371 (2007).
  Medline CASGoogle Scholar
• 87  Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther.319,879–886 (2006).
  Medline CASGoogle Scholar
• 88  Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K: Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol.74,477–487 (2007).
  Medline CASGoogle Scholar
• 89  Aslamkhan AG, Han YH, Yang XP, Zalups RK, Pritchard JB: Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in Madin–Darby canine kidney cells. Mol. Pharmacol.63,590–596 (2003).
  Medline CASGoogle Scholar
• 90  Lopez-Nieto CE, You G, Bush KT, Barros EJ, Beier DR, Nigam SK: Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney. J. Biol. Chem.272,6471–6478 (1997).
  Medline CASGoogle Scholar
• 91  Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB: Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J. Pharmacol. Exp. Ther.314,923–931 (2005).
  Medline CASGoogle Scholar
• 92  Fujita T, Brown C, Carlson EJ et al.: Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet. Genomics15,201–209 (2005).
  Medline CASGoogle Scholar
• 93  Erdman AR, Mangravite LM, Urban TJ et al.: The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am. J. Physiol. Renal Physiol.290,F905–F912 (2006).
  Medline CASGoogle Scholar
• 94  Motohashi H, Sakurai Y, Saito H et al.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol.13,866–874 (2002).
  Medline CASGoogle Scholar
• 95  Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol.13,1703–1710 (2002).
  Medline CASGoogle Scholar
• 96  Fukushima-Uesaka H, Maekawa K, Ozawa S et al.: Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab. Pharmacokinet.19,239–244 (2004).
  Medline CASGoogle Scholar
• 97  Saito S, Iida A, Sekine A et al.: Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J. Hum. Genet.47,576–584 (2002).
  Medline CASGoogle Scholar
• 98  Leabman MK, Huang CC, Kawamoto M et al.: Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics12,395–405 (2002).
  Medline CASGoogle Scholar
• 99  Kimura N, Masuda S, Tanihara Y et al.: Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet.20,379–386 (2005).
  Medline CASGoogle Scholar
• 100  Nigam SK, Bush KT, Bhatnagar V: Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat. Clin. Pract. Nephrol.3,443–448 (2007).
  Medline CASGoogle Scholar
• 101  Anzai N, Kanai Y, Endou H: Organic anion transporter family: current knowledge. J. Pharmacol. Sci.100,411–426 (2006).
  Google Scholar
• 102  Robertson EE, Rankin GO: Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol. Ther.109,399–412 (2006).
  Medline CASGoogle Scholar
• 103  Shitara Y, Sato H, Sugiyama Y: Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol.45,689–723 (2005).
  Medline CASGoogle Scholar
• 104  Marzolini C, Tirona RG, Kim RB: Pharmacogenomics of the OATP and OAT families. Pharmacogenomics5,273–282 (2004).
  CASGoogle Scholar
• 105  Wright SH: Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol. Appl. Pharmacol.204,309–319 (2005).
  Medline CASGoogle Scholar
• 106  Maeda T, Goto A, Kobayashi D, Tamai I: Transport of organic cations across the blood–testis barrier. Mol. Pharm.4,600–607 (2007).
  Medline CASGoogle Scholar
• 107  Pinsonneault J, Nielsen CU, Sadee W: Genetic variants of the human H⁺/dipeptide transporter PEPT2: analysis of haplotype functions. J. Pharmacol. Exp. Ther.311,1088–1096 (2004).
  Medline CASGoogle Scholar
• 108  Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther.304,223–228 (2003).
  Medline CASGoogle Scholar
• 109  Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos.33,434–439 (2005).
  Medline CASGoogle Scholar
• 201  NCBI Single Nucleotide Polymorphism Reference database www.ncbi.nlm.nih.gov/SNP/
  Google Scholar